Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
Author: Sanjay J. Mathew,Carlos A. Zarate, Jr.
Publsiher: Springer
Total Pages: 155
Release: 2016-11-25
ISBN 10: 3319429256
ISBN 13: 9783319429250
Language: EN, FR, DE, ES & NL

Ketamine for Treatment-Resistant Depression Book Review:

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
Author: Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke
Publsiher: Academic Press
Total Pages: 168
Release: 2020-10-01
ISBN 10: 0128210346
ISBN 13: 9780128210345
Language: EN, FR, DE, ES & NL

Ketamine for Treatment-Resistant Depression Book Review:

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Ketamine for Depression

Ketamine for Depression
Author: Dr. Stephen J. Hyde
Publsiher: Xlibris Corporation
Total Pages: 222
Release: 2015-09-04
ISBN 10: 1503509532
ISBN 13: 9781503509535
Language: EN, FR, DE, ES & NL

Ketamine for Depression Book Review:

Given the unacceptably high rates of suffering, disability and premature death experienced by people with treatment-resistant depression and the surprisingly low rates of problems arising from the use of ketamine to treat the disorder, this is a therapy that all patients and their doctors should be discussing. This book summarises the research that has been carried out into ketamine for the treatment of depression over the past 15 years and, most importantly, describes different ways of using ketamine that are both practical and cost–effective. Currently most ketamine therapy is given intravenously in specialised clinics at considerable expense, but the author has successfully treated patients with low-dose sublingual ketamine and his patients have been able to safely take this at home. Profits from the sales of this book will assist further research into the use of ketamine for the treatment of depression.

Repeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial

Repeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial
Author: Anonim
Publsiher: Anonim
Total Pages: 329
Release:
ISBN 10:
ISBN 13: OCLC:1051947420
Language: EN, FR, DE, ES & NL

Repeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial Book Review:

Background: Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. Methods: This randomised, double-blind, placebo-controlled pilot study compared a 4-week course of eight treatments of 100 mg ketamine or 4.5 mg midazolam. Each treatment was given as 10 separate IN sprays, self-administered 5 min apart. The study was stopped early due to poor tolerability after five treatment-resistant depressed participants were included. Feasibility, safety (acute and cumulative), cognitive and efficacy outcomes were assessed. Plasma ketamine and norketamine concentrations were assayed after the first treatment. Results: Significant acute cardiovascular, psychotomimetic and neurological side effects occurred at doses 100 mg ketamine. No participants were able to self-administer all 10 ketamine sprays due to incoordination; treatment time occasionally had to be extended (45 min) due to acute side effects. No hepatic, cognitive or urinary changes were observed after the treatment course in either group. There was an approximately two-fold variation in ketamine and norketamine plasma concentrations between ketamine participants. At course end, one participant had remitted in each of the ketamine and midazolam groups. Conclusions: IN ketamine, with the drug formulation and delivery device used, was not a useful treatment approach in this study. Absorption was variable between individuals and acute tolerability was poor, requiring prolonged treatment administration time in some individuals. The drug formulation, the delivery device, the insufflation technique and individual patient factors play an important role in tolerability and efficacy when using IN ketamine for TRD.

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION
Author: Mariane Quieroti Rodrigues
Publsiher: Anonim
Total Pages: 329
Release: 2017
ISBN 10:
ISBN 13: OCLC:1163811374
Language: EN, FR, DE, ES & NL

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION Book Review:

Introduction: Major depressive disorder is highly common with up to 50% to 60% of the patients not achieving adequate response following antidepressant treatment. In this scenario, ketamine emerges as an important alternative to conventional treatments, with its action of being an antagonist of N-methyl- D-aspartate (NMDA) receptor, once its has a quick and effective action. Ketamine is most frequently administered intravenous. However, oral, sublingual, transmucosal, intranasal, subcutaneous (SC), and intramuscular routes of administration have also been examined.Aim: This study aims to investigate whether SC ketamine is effective in the treatment of unipolar major depression and if it has more effective and sustainable response than electroconvulsivetherapy (ECT).Methods: Participants will be comprised of patients with unipolar depression resistant to conventional treatment, men and women, aged u2265 18 across a range of ethnicities, recruited from General Hospital Servidor of State of Su00e3o Paulo, Brazil. Participants will be separeted in two groups. The first one will recieve a SC administration of ketamine in the dose of 0,5mg/kg weekly, for 6 weeks. The second will be submitted to ECT treatment, two sessions a week, for at least 8 sessions. The response of each treatment will be evaluated and compared by MADRS questionnaire.Results: We expect that SC ketamine has a good response in the treatment of major depression and that it has a similar response compared to ECT.Conclusion: SC ketamine, once it is a secure, quick and simple procedure, is a promising alternative to the available treatments.

Intravenous Ketamine for Adults with Treatment-Resistant Depression Or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Intravenous Ketamine for Adults with Treatment-Resistant Depression Or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines
Author: Anonim
Publsiher: Anonim
Total Pages: 329
Release: 2019
ISBN 10:
ISBN 13: OCLC:1151537743
Language: EN, FR, DE, ES & NL

Intravenous Ketamine for Adults with Treatment-Resistant Depression Or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Book Review:

Ketamine

Ketamine
Author: Kenji Hashimoto,Soichiro Ide,Kazutaka Ikeda
Publsiher: Springer Nature
Total Pages: 189
Release: 2020-03-05
ISBN 10: 9811529027
ISBN 13: 9789811529023
Language: EN, FR, DE, ES & NL

Ketamine Book Review:

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.

Treatment-resistant Mood Disorders

Treatment-resistant Mood Disorders
Author: Andre Carvalho,Roger McIntyre
Publsiher: Oxford University Press, USA
Total Pages: 160
Release: 2014-05-01
ISBN 10: 0198707991
ISBN 13: 9780198707998
Language: EN, FR, DE, ES & NL

Treatment-resistant Mood Disorders Book Review:

Treatment-resistant major depression and bipolar disorder are highly prevalent and disabling conditions associated with substantial morbidity and mortality. The assessment and management of refractory patients with mood disorders is a major clinical challenge for mental health providers. Part of the Oxford Psychiatry Library (OPL) series, this pocketbook provides a concise view of the current definitions, assessment and evidence-based management of treatment-resistant mood disorders and reviews novel therapeutic targets for mood disorders, which may enhance the therapeutic armamentarium of clinicians in the near future. The pocketbook serves as a useful guide for mental health practitioners, including psychiatrists, clinical psychologists, trainees, and interested primary care physicians.

Modern Anesthetics

Modern Anesthetics
Author: Jürgen Schüttler,Helmut Schwilden
Publsiher: Springer Science & Business Media
Total Pages: 498
Release: 2008-01-08
ISBN 10: 9783540748069
ISBN 13: 3540748067
Language: EN, FR, DE, ES & NL

Modern Anesthetics Book Review:

Some important constraints of anesthesia must be taken into consideration when the pharmacological properties of modern anesthetics are discussed. The most imp- tant of these could be that the target effect be achieved preferably within seconds, at most within a few minutes. Similarly, offset of drug action should be achieved within minutes rather hours. The target effects, such as unconsciousness, are pot- tially life-threatening, as are the side effects of modern anesthetics, such as respi- tory and cardiovascular depression. Finally, the patient’s purposeful responses are not available to guide drug dosage, because, either the patient is unconscious, or more problematically, the patient is aware but unable to communicate pain because of neuromuscular blockade. These constraints were already recognised 35 years ago, when in 1972 Volume XXX entitled “Modern Inhalation Anesthetics” appeared in this Handbook Series. The present volume is meant as a follow up and extension of that volume. At the beginning of the 1970’s anesthesia was commonly delivered by inhalation, with only very few exceptions. The clinical understanding of that time considered anesthesia as a unique state achieved by any of the inhalation anesthetics, in- pendent of their specific molecular structure. “The very mechanism of anesthetic action at the biophase” was discussed within the theoretical framework of the “u- tary theory of narcosis”.

The ECT Handbook

The ECT Handbook
Author: I. Nicol Ferrier,Jonathan Waite
Publsiher: Cambridge University Press
Total Pages: 241
Release: 2019-07-04
ISBN 10: 1911623168
ISBN 13: 9781911623168
Language: EN, FR, DE, ES & NL

The ECT Handbook Book Review:

A thorough update to the 'must-have' guide to ECT for clinical psychiatrists, providing practical advice on safe and efficacious treatment.

Rapid Acting Antidepressants

Rapid Acting Antidepressants
Author: Anonim
Publsiher: Academic Press
Total Pages: 402
Release: 2020-06-29
ISBN 10: 0128201908
ISBN 13: 9780128201909
Language: EN, FR, DE, ES & NL

Rapid Acting Antidepressants Book Review:

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series

The Ketamine Papers

The Ketamine Papers
Author: Kenneth Ring,Stanislav Grof,Ralph Metzner,Stanley Krippner,Eli Kolp,Harris Friedman,Evgeny Krupitsky,Karl Jansen,Mark Sylvester,M. Scott Young,Anna Kolp,Wesley Ryan,Cole Marta,Ralph Koek,Stephen Hyde,Steven Levine,Terrence Early,Jeffrey Becker
Publsiher: Anonim
Total Pages: 448
Release: 2016-11-15
ISBN 10: 9780998276502
ISBN 13: 0998276502
Language: EN, FR, DE, ES & NL

The Ketamine Papers Book Review:

The Ketamine Papers opens the door to a broad understanding of this medicine's growing use in psychiatry and its decades of history providing transformative personal experiences. Now gaining increasing recognition as a promising approach to the treatment of depression, posttraumatic stress disorder (PTSD), and other psychological conditions, ketamine therapies offer new hope for patients and clinicians alike. With multiple routes of administration and practices ranging from anesthesia to psychotherapy, ketamine medicine is a diverse and rapidly growing field. The Ketamine Papers clarifies the issues and is an inspiring introduction to this powerful tool for healing and transformation---from its early use in the 1960s to its emerging role in the treatment of depression, suicidality and other conditions. This comprehensive volume is the ideal introduction for patients and clinicians alike, and for anyone interested in the therapeutic and transformative healing power of this revolutionary medicine.

Major Depressive Disorder

Major Depressive Disorder
Author: Roger S McIntyre
Publsiher: Elsevier Health Sciences
Total Pages: 202
Release: 2019-08-25
ISBN 10: 0323581323
ISBN 13: 9780323581325
Language: EN, FR, DE, ES & NL

Major Depressive Disorder Book Review:

Get a quick, expert overview of the key issues surrounding best practices and current consensus on major depressive disorder (MDD). This concise resource by Drs. Roger S. McIntyre, Carola Rong, Mehala Subramaniapillai, and Yena Lee consolidates today’s available information on this complex topic into one convenient resource, making it an ideal, easy-to-digest reference for both psychiatrists and primary care physicians. Covers genetics and epigenetics, brain structural abnormalities, cognition, neuroendocrine alterations, and inflammatory abnormalities as they relate to MDD. Contains chapters on psychiatric comorbidity, pharmacological treatments, neuromodulatory treatments, lifestyle interventions, internet-based/technology-based interventions, and glutamate alterations.

05 - KETAMINE ANTIDEPRESSANT ACTIONS IN ELECTROCONVULSIVE THERAPY OF TREATMENT-RESISTANT DEPRESSION

05 - KETAMINE ANTIDEPRESSANT ACTIONS IN ELECTROCONVULSIVE THERAPY OF TREATMENT-RESISTANT DEPRESSION
Author: Bruno Josu00e9 Prates
Publsiher: Anonim
Total Pages: 329
Release: 2017
ISBN 10:
ISBN 13: OCLC:1163811932
Language: EN, FR, DE, ES & NL

05 - KETAMINE ANTIDEPRESSANT ACTIONS IN ELECTROCONVULSIVE THERAPY OF TREATMENT-RESISTANT DEPRESSION Book Review:

Background and aims: Major depressive disorder affects approximately 5% of the population with nearly 1-third of patients failing to achieve remission, despite adequate pharmacological treatment [1]. Although electroconvulsive therapy (ECT) is the gold standard approach for treatment resistant depression (TRD), a considerable fraction of patients also show a delayed improvement or appear to be resistant to ECT. One of the most promising rapid-acting antidepressants is ketamine, a noncompetitive N-methyl-D-Aspartate receptor antagonist that can be used as an anesthetic during ECT to augment antidepressant efficacy [2].Data on ECTs using ketamine are both scarce and conflicting which lead the American Psychiatric Association to call for further studies [3]. We aim to clarify the potential synergism of ketamine and ECT for the treatment of TRD.Materials and methods: An experimental, non-randomized clinical trial with consecutive sampling of TRD patients with a HAM-D and PDAS scores u2265 23 was conducted. Patients that were initially assigned to 6 ECT sessions using thiopental anesthesia (ECT Std) but showed a very limited symptomatic relief were included in the study. Patients in Group 1 were then treated with further 6 ECT sessions using ketamine anesthesia (ECT Ket) whereas Group 2 maintained treatment with ECT Std (Fig. 1).Results: Clinical assessment showed no significant reduction in the mean HAM-D and PDAS scores for Group 1 but a significant reduction of the HAMD score of 38,8u00b12,4 to 13.4u00b110.55 (p

Depression: From Psychopathology to Pharmacotherapy

Depression: From Psychopathology to Pharmacotherapy
Author: J.F. Cryan,B.E. Leonard
Publsiher: Karger Medical and Scientific Publishers
Total Pages: 282
Release: 2010-11-17
ISBN 10: 3805596065
ISBN 13: 9783805596060
Language: EN, FR, DE, ES & NL

Depression: From Psychopathology to Pharmacotherapy Book Review:

Despite the availability of antidepressants for over 40 years, a substantial proportion of depressed patients do not respond adequately to treatment. Failure to respond effectively to treatment contributes to physical ill-health and psychiatric morbidity, often resulting in premature death of the depressed patient. The purpose of this volume is to consider the possible reasons for the limitations of the currently available antidepressants, to examine the advances in our understanding of the psychopathology of depression and how such knowledge may assist in the discovery of new methods of treatment. Leading international experts in this field discuss the possible underlying reasons for depression and limitations of current antidepressants. Opportunities for novel therapeutic approaches to dysfunctional circadian rhythms and mood disorders as well as current status and future perspectives for optimizing antidepressant management of depression are reviewed. This publication illustrates the breadth of the latest research and is valuable reading for psychiatrists, neuroscientists and pharmacologists.

Herbal Treatment of Major Depression: Scientific Basis and Practical Use

Herbal Treatment of Major Depression: Scientific Basis and Practical Use
Author: Scott D Mendelson
Publsiher: CRC Press
Total Pages: 422
Release: 2019-11-27
ISBN 10: 1000727467
ISBN 13: 9781000727463
Language: EN, FR, DE, ES & NL

Herbal Treatment of Major Depression: Scientific Basis and Practical Use Book Review:

This unique volume presents new understandings of the neurochemical nature of major depression, and how herbs and their constituent flavonoids and terpenes appear to address some of the mechanisms now thought to be involved. It explores how recent studies of the rapid antidepressant effects of ketamine inform neuroscientists about deep intracellular mechanisms of antidepressant action that have little to do with simple enhancement of monoaminergic activity. These mechanisms include actions on PI3K, Akt, mTOR, GSK3, BDNF, and other intracellular pathways. New theories of the pathophysiology underlying major depression, such as oxidative damage, inflammation, stress and insulin resistance are then explored. Key Features: Focuses on oxidative damage, inflammation, and metabolic syndrome. Explains that a significant percentage of people treated for major depression obtain little if any relief from standard antidepressant medications. These facts lead to discussion of herbs that can be used to treat major depression, as well as consideration of the scientific basis for how these herbs act. The antidepressant properties of 66 herbs are discussed, along with dosing and safety information.

Living without an Amygdala

Living without an Amygdala
Author: David G. Amaral,Ralph Adolphs
Publsiher: Guilford Publications
Total Pages: 430
Release: 2016-04-22
ISBN 10: 1462525954
ISBN 13: 9781462525959
Language: EN, FR, DE, ES & NL

Living without an Amygdala Book Review:

Bringing together leading researchers, this book comprehensively covers what is known about the amygdala, with a unique focus on what happens when this key brain region is damaged or missing. Offering a truly comparative approach, the volume presents research on rats, monkeys, and humans. It reports on compelling cases of people living without an amygdala, whether due to genetic conditions, disease, or other causes. The consequences for an individual's ability to detect danger and regulate emotions--and for broader cognitive and social functions--are explored, as are lessons learned about brain pathways and plasticity. The volume delves into the role of the amygdala in psychiatric disorders and identifies important directions for future research. Illustrations include six color plates.

Top Screwups Doctors Make and How to Avoid Them

Top Screwups Doctors Make and How to Avoid Them
Author: Joe Graedon,Teresa Graedon
Publsiher: Harmony
Total Pages: 336
Release: 2011-10-04
ISBN 10: 0307460932
ISBN 13: 9780307460936
Language: EN, FR, DE, ES & NL

Top Screwups Doctors Make and How to Avoid Them Book Review:

A primary care doctor is skeptical of his patient’s concerns. A hospital nurse or intern is unaware of a drug’s potential side effects. A physician makes the most “common” diagnosis while overlooking the signs of a rarer and more serious illness, and the patient doesn’t see the necessary specialist until it’s too late. A pharmacist dispenses the wrong drug and a patient dies as a result. Sadly, these kinds of mistakes happen all the time. Each year, 6.1 million Americans are harmed by diagnostic mistakes, drug disasters, and medical treatments. A decade ago, the Institute of Medicine estimated that up to 98,000 people died in hospitals each year from preventable medical errors. And new research from the University of Utah, HealthGrades of Denver, and elsewhere suggests the toll is much higher. Patient advocates and bestselling authors Joe and Teresa Graedon came face-to-face with the tragic consequences of doctors’ screwups when Joe’s mother died in Duke Hospital—one of the best in the world—due to a disastrous series of entirely preventable errors. In Top Screwups Doctors Make and How to Avoid Them, the Graedons expose the most common medical mistakes, from doctor’s offices and hospitals to the pharmacy counters and nursing homes. Patients across the country shared their riveting horror stories, and doctors recounted the disastrous—and sometimes deadly—consequences of their colleagues’ oversights and errors. While many patients feel vulnerable and dependent on their health care providers, this book is a startling wake-up call to how wrong doctors can be. The good news is that we can protect ourselves, and our loved ones, by being educated and vigilant medical consumers. The Graedons give patients the specific, practical steps they need to take to ensure their safety: the questions to ask a specialist before getting a final diagnosis, tips for promoting good communication with your doctor, presurgery checklists, how to avoid deadly drug interactions, and much more. Whether you’re sick or healthy, young or old, a parent of a young child, or caring for an elderly loved one, Top Screwups Doctors Make and How to Avoid Them is an eye-opening look at the medical mistakes that can truly affect any of us—and an empowering guide that explains what we can do about it. From the Hardcover edition.

Treatment Resistance in Psychiatry

Treatment Resistance in Psychiatry
Author: Yong-Ku Kim
Publsiher: Springer
Total Pages: 416
Release: 2018-10-29
ISBN 10: 9811043582
ISBN 13: 9789811043581
Language: EN, FR, DE, ES & NL

Treatment Resistance in Psychiatry Book Review:

This book reviews all the important aspects of treatment-resistant psychiatric disorders, covering issues such as definitions, clinical aspects, neurobiological correlates, treatment options, and predictors of treatment response. The book is divided into three sections, the first of which examines the most recent thinking on treatment resistance in psychiatry, including definition and epidemiology, paradigm shift in the study of the subjects, individual susceptibility and resilience, abnormal structural or functional connectivity, and insights from animal models. The second section then discusses treatment resistance in each of the major psychiatric disorders, with particular focus on the responsible clinical and biological factors and the available management strategies. Finally, more detailed information is presented on diverse pharmacological and non-pharmacological therapeutic interventions. The book, written by leading experts from across the world, will be of value to all who seek a better understanding of the clinical-neurobiological underpinnings and the development of management for treatment resistance in psychiatric disorders.

Cognition in Major Depressive Disorder

Cognition in Major Depressive Disorder
Author: Roger S. McIntyre,Danielle S. Cha,Joanna K. Soczynska
Publsiher: OUP Oxford
Total Pages: 128
Release: 2014-05-08
ISBN 10: 0191002623
ISBN 13: 9780191002625
Language: EN, FR, DE, ES & NL

Cognition in Major Depressive Disorder Book Review:

Part of the Oxford Psychiatry Library (OPL) series, Cognition in Major Depressive Disorder provides a succinct summary of cognitive deficits reported in patients with major depressive disorder (MDD) with a particular focus on aspects of measurement, underlying disease pathophysiology, implications for treatment and prevention. This book also provides readers an opportunity for clinical-based assessment of cognition and recommendations for how cognitive measurement and treatment is positioned in the management of individuals with mood disorders.